Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Cadonilimab + Capecitabine + Oxaliplatin
Indication/Tumor Type gastroesophageal junction adenocarcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive gastroesophageal junction adenocarcinoma predicted - sensitive Cadonilimab + Capecitabine + Oxaliplatin Phase III Actionable In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). 39843940
PubMed Id Reference Title Details
(39843940) First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Full reference...